Daiichi Sankyo Completes Phase II, Moves To Phase III With Oral Factor Xa Inhibitor
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Daiichi Sankyo said Dec. 8 that it would soon complete Phase II clinical trials of its oral Factor Xa inhibitor DU-176b, after it registered comparable safety and tolerability in non-valvular atrial fibrillation patients compared to those taking the anticoagulant warfarin
You may also be interested in...
Daiichi Sankyo Optimistically Ramping Up For Prasugrel Launch
Daiichi Sankyo CEO Takashi Shoda acknowledged during the company's third quarter results call that the delay in U.S. FDA approval of Effient (prasugrel), a novel platelet inhibitor that the company filed jointly with Eli Lilly in December 2007, has negatively affected the company net sales forecast
Daiichi Sankyo Optimistically Ramping Up For Prasugrel Launch
Daiichi Sankyo CEO Takashi Shoda acknowledged during the company's third quarter results call that the delay in U.S. FDA approval of Effient (prasugrel), a novel platelet inhibitor that the company filed jointly with Eli Lilly in December 2007, has negatively affected the company net sales forecast
Astellas, Daiichi Move Ahead With Factor Xa Programs
Astellas and Daiichi Sankyo both are on track to proceed to Phase III for their respective oral Factor Xa inhibitors, the companies indicated in second quarter earnings presentations on Nov. 7